An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes

被引：27

作者：

Voynova, Elisaveta ^{[1
]}

Tchorbanov, Andrey ^{[1
]}

Prechl, Jozsef ^{[2
]}

Nikolova, Milena ^{[3
]}

Baleva, Marta ^{[4
]}

Erdei, Anna ^{[2
,5
]}

Vassilev, Tchavdar ^{[1
]}

机构：

[1] Bulgarian Acad Sci, Inst Microbiol, Dept Immunol, BG-1040 Sofia, Bulgaria

[2] Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary

[3] Med Univ Sofia, Univ Hosp Alexandrovska, Dept Nephrol, Sofia, Bulgaria

[4] Med Univ Sofia, Univ Hosp Alexandrovska, Dept Allergol, Sofia, Bulgaria

[5] Eotvos Lorand Univ, Hungarian Acad Sci, Dept Immunol, Res Grp, Budapest, Hungary

来源：

IMMUNOLOGY LETTERS | 2008年 / 116卷 / 02期

关键词：

inhibitory B cell receptors; complement receptor 1 (CD35); SLE;

D O I：

10.1016/j.imlet.2007.12.016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is an urgent and unmet need for therapeutic agents targeting selectively disease-associated B-lymphocytes in autoantibody-mediated diseases. We have constructed a chimeric molecule able to cross-link cell surface immunoglobulin with the inhibitory complement receptor type 1 (CD35) on DNA-specific B cells from SLE (systemic lupus erythematosus) patients with the aim of selectively silencing them. This engineered molecule is made of copies of the DNA-mimotope peptide DWEYSVWLSN coupled to a monoclonal anti-CD35 antibody. We found that the DNA-like peptide chimera induced a dose-dependent decrease in the number of IgG anti-dsDNA antibody producing cells when PBMCs of lupus patients were cultured in its presence. Our data present evidence that clustering BCR and the inhibitory CRI on disease-associated autoreactive B-lymphocytes selectively suppresses autoantibody production. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：168 / 173

页数：6

共 22 条

[1] Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy [J].

Anolik, Jennifer H. ;

Barnard, Jennifer ;

Owen, Teresa ;

Zheng, Bo ;

Kemshetti, Sunil ;

Looney, R. John ;

Sanz, Inaki .

ARTHRITIS AND RHEUMATISM, 2007, 56 (09) :3044-3056

[2] Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].

Anolik, JH ;

Barnard, J ;

Cappione, A ;

Pugh-Bernard, AE ;

Felgar, RE ;

Looney, RJ ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590

[3] A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus [J].

Chan, OTM ;

Hannum, LG ;

Haberman, AM ;

Madaio, MP ;

Shlomchik, MJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (10) :1639-1647

[4] Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus [J].

Doerner, Thomas ;

Kaufmann, Joerg ;

Wegener, William A. ;

Teoh, Nick ;

Goldenberg, David M. ;

Burmester, Gerd R. .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (03)

[5] The therapeutic potential of anti-CD20 - What do B-cells do? [J].

Eisenberg, R ;

Looney, RJ .

CLINICAL IMMUNOLOGY, 2005, 117 (03) :207-213

[6]

ERDEI A, 1994, MED INTELL UNIT

[7] First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104 [J].

Iking-Konert, C ;

Stocks, S ;

Weinsberg, F ;

Engelbrecht, R ;

Bleck, E ;

Perniok, A ;

Fischer-Betz, R ;

Pincus, S ;

Nardone, L ;

Schneider, M .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1104-1112

[8] Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls [J].

Jacobi, A. M. ;

Goldenberg, D. M. ;

Hiepe, F. ;

Radbruch, A. ;

Burmester, G. R. ;

Doerner, T. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (04) :450-457

[9] Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes [J].

Józsi, M ;

Prechl, J ;

Bajtay, Z ;

Erdei, A .

JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2782-2788

[10] Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus [J].

Kaliyaperumal, A ;

Michaels, MA ;

Datta, SK .

JOURNAL OF IMMUNOLOGY, 2002, 168 (05) :2530-2537

← 1 2 3 →